US Pharma MarketingViridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful veligrotug through clinical trials and Viridian aims to challenge Amgen in a blockbuster market, and it's now tapped Chinese CDMO giant WuXi Biologics in a manufacturing pact.
Viridian aims to challenge Amgen in a blockbuster market, and it's now tapped Chinese CDMO giant WuXi Biologics in a manufacturing pact.
Source: FiercePharma